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months (range, 1.6 to 31.2 months). There was
no correlation between survival and radiotherapy
dose, .sex, pretreatment WHO performance
status and tumor localization.
Our results confirm poor prognosis in
glioblastoma multiforme. New more effective
therapeutic approaches are sorely needed in this
tumour.
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The p53 is transcriptional factor that
enhances the rate of transcription of six or
seven known genes which play important role in
cell cycle regulation. The human p53 protein
contains 393 amino acids and has been divided
structurally and functionally into four domains.
The p53 gene and its protein product have been
studied since it became clear that slightly more
than 50% of human cancers contain mutations
in this gene. A study of mutational spectrum at
the p53 gene are localized predominantly in the
DNA-binding domain of the protein (exons 4-9).
The nature of this changes is most commonly a
missense mutation in one allele followed by a
reduction to homozygosity, producing a faulty
protein. Deletions or chain termination mutations
are more rarely.
Mutations in p53· gene have been also
found in breast cancer in 30-40% of cases. Kind
of these mutations suggest that enviromental
mutagens may play important role in arising of
this type of canceLlt is observed that in West
Poland breast cancer occures more frequently
then in other areas of the country; the highest
numbers of cases are found in GreatPoland still
now for unknown reasons. In this work 48 cases
of breast cancer were studied. 12 different
mutations in p53 were found. This mutations
were then compared with datebase catalogs
containing mutations in p53. Only 3 from 12
found mutations are the same as reported in
datebase. Nine of them were not observed
before what may suggest that specific
mutational spectrum in patients with breast
cancer from GreatPoland exists. Futher studies
involving greater number of cases are needed to
confirm this observation. .
IS ACUTE MUCOSITIS DOSE LIMITING FOR ALTERED FRACTIONATED RADIOTHERAPY?
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There is now a substantial number of studies
on radiotherapy for head and neck cancer using
altered fractionation schedules.
Accumulated dose/week (AD) vs incidence
and severity of acute mucositis
In conventional radiotherapy given in 1.6-2.0
Gy fractions up to total dose of about 70 Gy,
confluent mucositis (CM) is generally reached at
day 22. The threshold for the CM appears to be
around 20 Gy and the CM usually develops
about 9 days after delivering that dose.
However, some studies suggest that the onset
of CM may depend on accumulated dose/week
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and the larger AD is the sooner CM is reached.AII
these observations suggest that the intensity of
acute epithelial reactions, and likely other H-type-
like tissues reflects the balance between the rate
of cell killing by irradiation and the rate of
regeneration of surviving stem cells. Once a
critical level of survival cells has been attained, a
certain type of clinical damage will develop at a
rate only determined by the cellular kinetics of the
tissue. When a peak in the CM is reached, further
stem cell killing can not produce an increase in
intensity of acute reactions, but could be manifest
as prolonged time to heal the reactions.
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